U.S. FDA Approves Expanded Use of BristolMyers Squibbs Daklinza daclatasvir for Additional Challengingtotreat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 5 2016

Media coverage

1

Media coverage

  • TitleU.S. FDA Approves Expanded Use of BristolMyers Squibbs Daklinza daclatasvir for Additional Challengingtotreat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date2/5/16
    PersonsFred Poordad